🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

BRIEF-Valeant CEO says double digit organic growth will continue

Published 2015-12-16, 08:40 a/m
© Reuters.  BRIEF-Valeant CEO says double digit organic growth will continue
BHC
-

Dec 16 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX)
VRX.TO
* Valeant CEO says will not budget research and development
as a certain percentage of sales, but will review it regularly
* Valeant CEO says Addyi sales expected at $100 million to
$150 million in 2016
* Valeant says anticipates $250 million loss in revenue in
q4 due to Philidor situation
* Valeant says prescriptions dropped 20 percent in the
fourth quarter as it lost all Philidor covered scripts
* Valeant CEO says double digit organic growth will continue
in the years after 2016
* Valeant CEO says employee retention plan has worked and
has only lost two sales representatives in the dermatology
business
* Valeant says canceled all price increases during the
fourth quarter
* Valeant says employee retention bonuses targeted at $75
million in 2016


Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.